Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.

@article{Garca2011GemcitabineAD,
  title={Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.},
  author={Jorge A. Garc{\'i}a and Thomas E. Hutson and Dale Randall Shepard and Paul V. Elson and Robert Dreicer},
  journal={Cancer},
  year={2011},
  volume={117 4},
  pages={
          752-7
        }
}
BACKGROUND Docetaxel is the standard of care for patients with metastatic, castrate-resistant prostate cancer (CRPC). Gemcitabine is a nucleoside analogue with broad antitumor activity. In a phase 2 study of combined docetaxel and gemcitabine, the authors assessed its safety and activity in patients with chemotherapy-naive, metastatic CRPC. METHODS Eligible patients had untreated, metastatic CRPC with radiologic and/or biochemical evidence of progression after antiandrogen withdrawal with… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Similar Papers

Loading similar papers…